Cytophage Develops Freeze-Dried Phage Tablets For Poultry
FULL DISCLOSURE: This is sponsored content for Cytophage Technologies.
Cytophage Technologies (TSXV: CYTO) has announced the launch of a simplified application option for its bacteriophages that it believes will set itself apart within the phage industry globally.
The company has developed a lyophilized phage tablet intended to treat multiple types of bacteria, including E. coli and Salmonella, throughout the lifecycle of poultry. The use of lyophilized phage tablets is providing an alternative to the liquid form that is presently used in the industry, which most often requires a cold chain.
”The importance of eliminating the need for a cold chain cannot be overstated. Offering phages in lyophilized form represents a competitive advantage over other phage producers who have only liquid products that require refrigeration. Our innovative manufacturing increases our products’ heat tolerance and shelf-life,” commented Dr Steven Theriault.
READ: Cytophage Enters Letter Of Intent With Major Singapore-Based Agrifood Company
The tablets are freeze dried and stabilized, which enable Cytophage’s phage products to be more easily used in hot climates such as Southeast Asia. The tablets are ready to use, dose controlled, and dissolve in water for application.
Development of the tablet is said to be a direct response to Cytophage working with the poultry industry on phage products that assist in reducing the use of broad-spectrum antibiotics, and replacing those antibiotics with target phages. The firm intends to leverage the new product format across its existing and pending product lines globally.
Cytophage Technologies last traded at $0.35 on the TSX Venture.
FULL DISCLOSURE: Cytophage Technologies is a client of Canacom Group, the parent company of The Deep Dive. Canacom Group is currently long the equity of Cytophage Technologies. The author has been compensated to cover Cytophage Technologies on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.
